Psychotropic drug tenoten activates mitogen-activated MAP/ERK kinase regulatory cascade controlling the neuroprotective effects

Bulletin of Experimental Biology and Medicine

Volumn 144, Issue 3, 2007, Pages 319-321

  Epstein, O I ^a   Vorobieva, O V ^b   Grinkevich, L N ^b   Kharchenko, O A ^b   Shtark, Mark B ^c  

^a Materia Medica Holding R   (Russian Federation)

^b PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^c INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

Author keywords

Antidepressants; Central nervous system; Helix lucorum; Mitogen activated ERK protein kinases; Tenoten

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANXIOLYTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE; PROPROTEN; PROTEIN ANTIBODY; PROTEIN S 100; PSYCHOTROPIC AGENT; TENOTEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME REGULATION; GANGLION; INCUBATION TIME; MOLLUSC; NEUROPROTECTION; NONHUMAN; TRANQUILIZING ACTIVITY; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANXIETY; DEPRESSIVE DISORDER; ENZYME ACTIVATION; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; GANGLIA; HELIX (SNAILS); HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; NEUROPROTECTIVE AGENTS; PSYCHOTROPIC DRUGS; S100 PROTEINS;

HELIX LUCORUM;

EID: 37749031427     PISSN: 00074888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10517-007-0322-5     Document Type: Article

References (15)

1. L. N. Grinkevich, P. D. Lisachev, K. A. Baranova, and O. A. Kharchenko, Ros. Fiziol. Zh., 92, No. 5, 536-545 (2006).
2. S. Davis, P. Vanhoutte, C. Pages, et al., J. Neurosci., 20, No. 12, 4563-4572 (2000).
3. Y. Dwivedi, H. S. Rizavi, R. C. Roberts, et al., J. Neurochem., 77, No. 3, 916-928 (2001).
4. H. Einat, P. Yuan, T. D. Gould, et al., J. Neurosci., 23, No. 19, 7311-7316 (2003).
5. O. I. Epstein, A. Beregovoi, N. S. Sorokina, et al., Front. Biosci., No. 8, a79-a84 (2003).
6. O. I. Epstein, I. F. Pavlov, and M. B. Shtark, Evid. Based Complement. Alternat. Med., 3, No. 4, 541-545 (2006).
7. O. I. Epstein, T. A. Zapara, O. G. Simonova, et al., Front. Biosci., No. 9, 809-815 (2004).
8. D. R. Kaplan and F. D. Miller, Curr. Opin. Neurobiol., 10, No. 3, 381-391 (2000).
9. J. M. Kornhauser and M. E. Greenberg, Neuron, 18, No. 6, 839-842 (1997).
10. S. V. Kyosseva, Int. Rev. Neurobiol., 59, 201-220 (2004).
11. K. C. Martin, D. Michael, J. C. Rose, et al., Neuron, 18, No. 6, 899-912 (1997).
12. X. Tao, S. Finkbeiner, D. B. Arnold, et al., Ibid., 20, No. 4, 709-726 (1998).
13. G. M. Thomas and R. L. Huganir, Nat. Rev. Neurosci., 5, No. 3, 173-183 (2004).
14. S. Treves, E. Scuatri, M. Robert, et al., Biochemistry, 36, No. 38, 11498-11503 (1997).
15. D. B. Zimmer, E. H. Cornwall, A. Landar, and W. Song, Brain Res. Bull., 34, No. 4, 417-429 (1995).